Biomarker ID | 812 |
PMID | 22078333 |
Year | 2012 |
Biomarker | Prostate Helth Index (phi) |
Biomarker Basis | Concentration Based |
Biomolecule | Protein |
Source | Blood |
Subjects | Humans |
Regulation | Upregulated in Tumor Stage pt3 |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 1.03 (95% CI: 1.019–1.040); Multivariate: 1.021 (95% CI: 1.009–1.034); |
Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | pathological stage pt2 Vs pathological stage pt3 |
Type of Biomarker | Prognostic |
Cohort | 350 patients with prostate cancer were chosen. 350 patients with prostate cancer were chosen. (n=69) for pt2a,b , (n=39) for pt2c , (n=60) for pt3a, (n=250) for pt3b |
Senstivity | 90.7 % (95% CI: 83.6–95.5) |
Specificity | 28.5 % (95% CI: 22.9–34.6) |
AUC | 0.719 |
Accuracy | NA |
Level Of Significance | p<0.0001 |
Method Used | UniCel DxI800 Immunoassay System analyser (Beckman Coulter Inc., Brea, CA, USA) |
Clinical | No |
Remarks | Sensitivity, Specificity calculated at 3 different criterions |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | KLK3 |